bluebird bio (NASDAQ:BLUE) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of bluebird bio (NASDAQ:BLUE) in a research report sent to investors on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for bluebird bio’s FY2024 earnings at ($1.31) EPS.

Other analysts also recently issued reports about the company. Robert W. Baird reduced their target price on bluebird bio from $7.00 to $6.00 and set an outperform rating for the company in a research note on Thursday, August 15th. Royal Bank of Canada reissued a sector perform rating and issued a $4.00 price objective on shares of bluebird bio in a research note on Thursday, August 15th. JPMorgan Chase & Co. lowered bluebird bio from an overweight rating to a neutral rating in a research report on Thursday, August 15th. Barclays reduced their price target on shares of bluebird bio from $8.00 to $4.00 and set an overweight rating for the company in a research report on Thursday, August 15th. Finally, Bank of America lowered their price objective on shares of bluebird bio from $4.00 to $3.00 and set a buy rating on the stock in a report on Thursday, August 15th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and a consensus target price of $4.74.

bluebird bio Stock Down 1.0 %

Shares of BLUE stock opened at $0.50 on Monday. The firm has a 50 day moving average of $0.86 and a 200-day moving average of $1.00. The company has a market cap of $54.12 million, a price-to-earnings ratio of -0.67 and a beta of 0.75. bluebird bio has a 52 week low of $0.48 and a 52 week high of $5.53.

Institutional Investors Weigh In On bluebird bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC boosted its stake in shares of bluebird bio by 48.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after buying an additional 13,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in bluebird bio by 189.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 23,933 shares during the last quarter. Allegheny Financial Group LTD bought a new position in bluebird bio in the 2nd quarter valued at $25,000. Dynamic Technology Lab Private Ltd bought a new position in bluebird bio in the 4th quarter valued at $37,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of bluebird bio by 113.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 29,113 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.